{"id":4142,"date":"2025-07-17T12:11:19","date_gmt":"2025-07-17T09:11:19","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4142"},"modified":"2025-11-03T20:21:36","modified_gmt":"2025-11-03T17:21:36","slug":"insmed-ins1201-gene-therapy-phase-1-clinical-trial-nct06817382","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/insmed-ins1201-gene-therapy-phase-1-clinical-trial-nct06817382\/","title":{"rendered":"Comienza el ensayo cl\u00ednico de fase 1 de la terapia g\u00e9nica INS1201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Insmed anunci\u00f3 en la p\u00e1gina publicada en ClinicalTrials.gov con el ID NCT06817382 que se iniciar\u00e1n los ensayos de fase 1 de la terapia g\u00e9nica INS1201 desarrollada para la distrofia muscular de Duchenne.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Tabla de contenido<\/h2><nav><ul><li><a href=\"#bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Ensayo cl\u00ednico de fase 1 de terapia g\u00e9nica INS1201<\/a><\/li><li><a href=\"#what-is-insmed-ins-1201-gene-therapy\">\u00bfQu\u00e9 es la terapia g\u00e9nica Insmed INS1201?<\/a><\/li><li><a href=\"#bbm-d-101-clinical-trial-nct-07058662\">Ensayo cl\u00ednico INS1201 \u2013 NCT06817382<\/a><\/li><li><a href=\"#bbm-d-101-phase-1-2-participation-criteria\">Criterios de participaci\u00f3n de la Fase 1 del INS1201<\/a><\/li><li><a href=\"#how-can-i-contact-with-belief-bio-med\">\u00bfC\u00f3mo puedo contactar con Insmed?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Ensayo cl\u00ednico de fase 1 de terapia g\u00e9nica INS1201<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">El objetivo principal de este estudio es evaluar la seguridad y tolerabilidad de una dosis \u00fanica de INS1201 mediante administraci\u00f3n IT en participantes masculinos ambulatorios con DMD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-insmed-ins-1201-gene-therapy\">\u00bfQu\u00e9 es la terapia g\u00e9nica Insmed INS1201?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">El INS1201 se dirige directamente al sistema nervioso central y se administra por v\u00eda intratecal, a diferencia del Elevidys, que necesita una inyecci\u00f3n intravenosa sist\u00e9mica. Se pretende abordar los problemas de seguridad y eficacia de los tratamientos g\u00e9nicos sist\u00e9micos mediante esta estrategia de administraci\u00f3n focalizada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La administraci\u00f3n intratecal reduce dr\u00e1sticamente la dosis necesaria entre diez y cincuenta veces, lo que evita la toxicidad sist\u00e9mica y los efectos no deseados al concentrar el medicamento donde se necesita. A pesar de obst\u00e1culos como la lesi\u00f3n de la m\u00e9dula espinal, el da\u00f1o a los nervios y el riesgo de infecciones, esto podr\u00eda proporcionar a los pacientes una opci\u00f3n m\u00e1s segura y posiblemente m\u00e1s exitosa, especialmente a la luz de los problemas de seguridad asociados con las grandes dosis de vectores virales utilizados en la terapia intravenosa.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-clinical-trial-nct-07058662\">Ensayo cl\u00ednico INS1201 \u2013 NCT06817382<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inicio del estudio (estimado)<\/strong>: 2025-05-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n primaria (estimada)<\/strong>: 2028-01-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n del estudio (estimada)<\/strong>: 2028-03-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 12 (Masculino)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ubicaciones<\/strong>: EE.UU<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edades elegibles para estudiar<\/strong>: 2 a\u00f1os a 4 a\u00f1os (ni\u00f1o)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-phase-1-2-participation-criteria\">Criterios de participaci\u00f3n de la Fase 1 del INS1201<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Las personas deben cumplir con los requisitos de inclusi\u00f3n para ser elegibles. Si una persona padece otra enfermedad o est\u00e1 en tratamiento que podr\u00eda impedirle recibir terapia g\u00e9nica, es posible que no pueda participar. Puede consultar el conjunto completo de criterios de inclusi\u00f3n y exclusi\u00f3n haciendo clic en este enlace del estudio. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06817382\" target=\"_blank\" rel=\"noreferrer noopener\">NCT06817382<\/a> \u2013.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-i-contact-with-belief-bio-med\">\u00bfC\u00f3mo puedo contactar con Insmed?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre<\/strong>: Informaci\u00f3n m\u00e9dica de Insmed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de tel\u00e9fono<\/strong>: 18444467633<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Correo electr\u00f3nico<\/strong>: medicalinformation@insmed.com<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensayos cl\u00ednicos para la distrofia muscular de Duchenne (Lista de todas las investigaciones)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Insmed was announced on the page published on ClinicalTrials.gov with the ID NCT06817382 that the phase 1 trials of INS1201 gene therapy developed for Duchenne Muscular Dystrophy will be initiated. INS1201 Gene Therapy Phase 1 Clinical Trial The primary objective of this study is to evaluate the safety and tolerability of a single dose of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4148,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,61,173,174,172],"class_list":["post-4142","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-gene-therapy","tag-ins1201","tag-ins1201-gene-therapy","tag-insmed"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4142"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4148"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4142"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}